What is Genialis, Inc?
Genialis, Inc. is a precision oncology company dedicated to overcoming the hurdles in cancer treatment, particularly patient variability in drug response and the high attrition rates in clinical trials. By leveraging sophisticated AI models and a robust multiomics data infrastructure, Genialis provides critical therapeutic intelligence throughout the drug development lifecycle. Their proprietary Genialis Supermodel is designed to enhance patient stratification and improve the success rates of oncology drug development, aiming to bring effective treatments to patients more efficiently.
How much funding has Genialis, Inc raised?
Genialis, Inc has raised a total of $15.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$13M
Angel/Seed (2017): $2.3M with participation from Redalpine and First Star Ventures
Series A (2023): $13M led by First Star Ventures, Taiwania Capital, and Debiopharm
Key Investors in Genialis, Inc
First Star Ventures
First Star Ventures is an investment firm that backs technical founders in advanced technologies like AI/ML and techbio, leveraging its network to scale hard computing tech startups.
Taiwania Capital
Taiwania Capital is an investment entity that participated in Genialis's Series A funding round.
Debiopharm
Debiopharm Investment, the investment division of Debiopharm Group, focuses on safeguarding capital and generating financial returns, with interests in private equity.
What's next for Genialis, Inc?
The recent major strategic investment signals a strong validation of Genialis's AI-driven approach to drug development in oncology. This capital will likely fuel further expansion of their AI platforms, enhance data integration capabilities, and support the progression of their pipeline candidates through critical development stages. Genialis is poised to deepen its impact on precision medicine, potentially leading to faster clinical trial outcomes and the introduction of novel cancer therapies.
See full Genialis, Inc company page
